
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Transfection is the mechanism that enables exogenous nucleic acids to enter cells while avoiding the cell membrane. The exogenous nucleic acids plasmid DNA, RNA, siRNA, and oligonucleotides are frequently employed. Nucleic acids affect gene expression after being introduced into cells by causing an interest gene to be overexpressed or silenced.
Effective transfection of nucleic acids, such as DNA or RNA, into cells is achieved using lipid reagents appropriate for tissue-targeted delivery of biomaterials. A non-toxic, biodegradable lipid reagent is required.
The delivery of genes that encourage the proliferation and differentiation of cells in a particular tissue using lipid reagents is a technique used in tissue engineering.
Such lipid reagents are created to release their therapeutic payload in response to particular stimuli, such as the several enzymes found in the target tissue. To ensure safety and effectiveness, lipid reagents must be meticulously created.
Lipid-based transfection agents, which are frequently employed for in vitro applications, are not suitable for use in living organisms because they can trigger an immunological reaction and damage organs.
Without the aid of a transfection technique, nucleic acids cannot be transfected into cells. There are a number of physical techniques, including microinjection, sonoporation, and electroporation, however these procedures are difficult and generally harmful to mammalian cells.
Chemical-mediated transfection provides a fantastic alternative to address these problems because of its simplicity of usage, high transfection efficiency, and excellent cell survival.
The Global Lipid Transfection Reagents Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The act of artificially introducing nucleic acids (DNA or RNA) into eukaryotic cells is known as transfection. As the name suggests, chemicals used in transfection are known as transfection reagents.
Users are frequently bothered during the transfection process by the low transfection efficacy, restricted application range, high toxicity, difficult operation, and pricey cost of transfection reagents. The ideal solution for these issues is linear PEI MW 40000.
With more than 50,000 citations, Invitrogen Lipofectamine reagents have surpassed all other transfection reagents in popularity. Due to their widespread recognition as the best and most dependable products on the market, you keep using these reagents. With great efficiency and exceptional usability, Lipofectamine reagents can reliably transfect a wide variety of cell types.
Specific methods for Thermo Fisher Scientific Inc. Lipofectamine reagents have been developed for effectiveness, viability, and repeatability across a variety of cell types. In particular for a fresh cell line, this can be an excellent starting point.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |